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Abstract
Background: Primary orthostatic tremor (POT) is an infrequent disorder whose physiopathology is unknown. Current medication is largely ineffective or only
offers mild benefits.
Case Report: A 75-year-old female with refractory POT treated with 4 mg/day of perampanel achieved complete symptom resolution. Owing to adverse effects,
the patient reduced intake to 2 mg/day, but even at this lower dose the benefit was maintained.
Discussion: We report the complete resolution of POT symptoms using low doses of perampanel, an antiepileptic drug that blocks glutamate-mediated post-
synaptic excitation. Further controlled studies are necessary to confirm this finding.
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Introduction
Primary orthostatic tremor (POT) is an infrequent disorder character-
ized by tremor and unsteadiness. It only occurs when the patient is
upright and immobile, and stops once the patient walks, sits down, or lies
down.1 Patients report a feeling of instability that impacts their quality of
life and may affect their activities of daily living; consequently, many such
patients experience anxiety, depression, and social phobia.2
The physiopathology is still unclear, although neuroimaging and
functional studies suggest that the brainstem, cerebellum, thalamus,
and primary motor cortex are involved.3 Medication is largely ineffec-
tive, although it may provide some mild relief. Deep brain stimulation
has been shown to have some benefit in severe cases.1
We report the case of a patient with refractory POT that had
developed 15 years previously, whose symptoms were completely
resolved with low doses of perampanel, an orally active, selective,
non-competitive a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptor antagonist.
Case report
A 75-year-old female with a medical history of hypertension,
asthma, and hypothyroidism had been diagnosed with POT 15 years
earlier. This condition led to a progressive functional decline over the
years that significantly affected the patient’s autonomy and quality of
life. She had no psychiatric or family history of tremor or other neuro-
logical diseases. The neurological examination was normal, revealing
no tremor in the upper limbs or signs of parkinsonism.
A surface electromyography (EMG) study of the lumbar axial muscles
with the patient in the standing position showed a 14 Hz EMG rhythmic
burst pattern (Figure 1).
The patient had previously been unsuccessfully treated with several
drugs (daily dose): clonazepam (1.5 mg), gabapentine (1200 mg),
pregabaline (300 mg), primidone (750 mg), levodopa (300 mg), levetir-
acetam (1000 mg), topiramate (200 mg), and zonisamide (200 mg).
Treatment with perampanel was begun with 4 mg/day (after a
4-week introductory dose of 2 mg/day). At the 2-month follow-up
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outpatient visit, the patient described full symptomatic relief, indicating,
for instance, that in the kitchen and at the bus stop she could now
stand rather than be forced to sit. The patient subjectively rated her
improvement as 100%. As an adverse effect she experienced dizziness
and reduced her dose to 2 mg/day; despite the low dose, she remains
completely asymptomatic. A new EMG study revealed the persistence
of 14 Hz rhythmic bursts.
Discussion
We report a case of POT, which, when treated with perampanel
(2–4 mg/day), achieved complete resolution of symptoms. To the best
of our knowledge, there have been no reports about the use of this
drug to effectively treat POT.
The current medication for POT is only partially effective and
complete resolution using those drugs is exceptional.1 Currently, the
only treatment is symptomatic rather than etiological. The effective-
ness of clonazepam and gabapentine—considered to be first-line
agents—has been demonstrated in small clinical trials.4,5 Primidone
has been shown to have some short-term effect,1,4,6 and valproic acid,
propranolol, and bromazepam have been shown to induce a mild
response.4 Studies have described patients in which POT preceded
Parkinson disease, for whom levodopa or pramipexole may work.4,7–9
In non-responders, bilateral thalamic deep brain stimulation of the
ventral intermediate nucleus can offer some benefit.10,11
Perampanel is a first-in-class selective, non-competitive AMPA
receptor antagonist that functions by blocking glutamate activity in the
post-synaptic AMPA receptors, which are the predominant mediator
of excitatory neurotransmission in the brain.12 It has been licensed and
marketed as an antiepileptic drug and is indicated for patients with
partial-onset seizures and primary generalized tonic–clonic seizures.
Positive effects have been reported for some patients with epileptic
myoclonic jerks, idiopathic generalized epilepsy, and progressive myo-
clonic epilepsy.13,14
Interestingly, although our patient achieved a complete resolution
of symptoms, neurophysiology revealed the persistence of subclinical
EMG findings for POT. This would confirm a symptomatic rather
than an etiological effect.
Bearing in mind its mechanism of action, the fact that perampanel
has proven to be an effective treatment for our patient suggests that
glutamate neurotransmitters—also involved in the pathophysiology of
essential tremor15—are involved in the physiopathology of POT.16,17
Another possibility is that the neurochemical circuits and structures
involved in the pathophysiology of POT are segmented, with some
circuits modulating tremor frequency (pacemaker function) and other
circuits modulating tremor amplitude through increased glutamate-
mediated excitatory activity within the pacemaker circuit. Perampanel—
which prevents excitation of post-synaptic membranes by inhibiting
the glutamate receptors—may therefore modulate flows in reciprocal
circuits with abnormal oscillatory neuronal activity and, in this way,
significantly regulate tremor amplitude, even though the primary
pacemaker may not modify high tremor frequency.18–20
To sum up, we report a case of complete resolution of POT
symptoms using low doses of perampanel. Further controlled studies
are necessary to confirm this finding. We would recommend a clinical
trial of perampanel in patients with refractory POT to current
treatments.
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